Researchers in San Francisco have found that MR imaging can accurately predict recurrence and development of metastatic disease in patients who are about to undergo radiation therapy for prostate cancer. Study findings suggest a stronger role for MRI in the management of the condition.
Researchers in San Francisco have found that MR imaging can accurately predict recurrence and development of metastatic disease in patients who are about to undergo radiation therapy for prostate cancer. Study findings suggest a stronger role for MRI in the management of the condition.
Nearly 200,000 new cases of prostate cancer will be diagnosed in the U.S. during 2008, according to the National Cancer Institute. Scientific evidence shows that early diagnosis and treatment may assure a five-year survival rate of almost 100%. Biopsy remains the standard of care for diagnosis and staging, but it can miss disease features that are critical for tailoring treatments that could improve the clinical outcomes of patients at higher risk of recurrence.
MRI could do a much better job in this setting, according to coauthor Dr. Fergus V. Coakley, a professor of radiology and urology at the University of California, San Francisco.
"This is the first study to show that MRI detection and measurement of the spread of prostate cancer outside the capsule of the prostate is an important factor in determining outcome for men scheduled to undergo radiation therapy," Coakley said.
Coakley and colleagues retrospectively analyzed images from 80 men with prostate cancer who had an MR scan before undergoing external-beam radiation therapy. The investigators recorded tumor findings, treatment, and outcomes and used a regression analysis technique to correlate survival with specific characteristics of prostate disease. They found that MRI could accurately predict post-treatment recurrence and disease spread. They published their findings in the April issue of Radiology.
Three of five patients with extracapsular extension larger than 5 mm on MRI developed metastases at 24, 43, and 63 months after therapy. Univariate Cox analysis showed that correlations between baseline serum prostate-specific antigen level, presence of extracapsular extension at MR imaging, and degree of extracapsular extension in relation to the development of metastases were all statistically significant (p<0.05). Multivariate Cox analysis also showed that the mean diameter of extracapsular extension could be an independent prediction variable (p = 0.007).
According to Coakley, an important question raised by the study is whether every patient planning to undergo external-beam radiation therapy for prostate cancer should have endorectal MRI. There is a good argument that the information provided by MRI is prognostically useful and may influence therapy.
The reality, however, is that the technology and interpretive expertise required are still not widely available and that reimbursement policies by third-party payers vary. Larger and more systematic prospective multicenter trials may help elucidate the true role and utility of endorectal MRI in this setting, he said.
"The decision to use such advanced imaging should be discussed with the patient by his treating physicians, with acknowledgment of local practice and insurance coverage issues," Coakley said.
For more information from the Diagnostic Imaging archives:
High-field MR begins to define parameters of prostate cancer
Young Investigator Awards add luster to MRI's scientific stars
Three-D adds accuracy to prostate evaluation
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.